Title : Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pub. Date : 2015 Mar 5

PMID : 25686603






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) confers resistance to all approved ABL1 inhibitors except ponatinib, which has toxicity limitations. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens